EMEA-000191-PIP01-08-M05

Invented name	Vfend
Active substance	voriconazole
Therapeutic area	Infectious diseases
Decision number	P/0151/2013
PIP number	EMEA-000191-PIP01-08-M05
Pharmaceutical form(s)	Film-coated tablet Powder for oral suspension Powder for solution for infusion
Condition(s) / indication(s)	Treatment of candidaemia in non-neutropenic patients Treatment of fluconazole-resistant serious invasive Candida infections (including C. krusei) Treatment of invasive aspergillosis Treatment of serious fungal infections caused by Scedosporium spp. and Fusarium spp.
Route(s) of administration	Oral use Intravenous use
Contact for public enquiries	Pfizer Limited E-mail: pip_enquiries@pfizer.com United Kingdom Tel. +44 (0)1304 646607 Fax +44 (0)1304 653601
Decision type	P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Compliance procedure number	EMEA-C-000191-PIP01-08-M05
Compliance opinion date	09/08/2013
Compliance outcome	positive

Add your rating

★ ★ ★ ★ ★